-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 16, 2021, Biogen and Eisai announced that they are expected to start a large confirmatory clinical trial in May next year to further evaluate Alzheimer's disease (AD) monoclonal antibodies Efficacy of therapy Aduhelm (aducanumab)
Aducanumab is a monoclonal antibody that directly targets amyloid beta (Aβ)
Aduhelm's approval in June was based on the accelerated approval channel
Bojian’s press release pointed out that the trial will recruit more than 1,300 early-stage AD patients.
Reference materials:
[1] Biogen Preps for Post-Approval Testing of Controversial Alzheimer's Drug.
[2] All Approvals and Tentative Approvals December 2021.